Ibuprofen Decoy
Pain-reliever ibuprofen makes enzyme oxidize styrene with hydrogen peroxide
Advertisement
enzymes can be efficient biocatalysts for organic synthesis, but often only work on a small range of specific substrates. Yoshihito Watanabe and colleagues at Nagoya University and RIKEN (Japan) have tricked enzymes into catalyzing reactions between molecules of choice, they report in Chemistry—An Asian Journal. By using organic acids, including the pain reliever ibuprofen, they mimicked the natural substrate.
The researchers used one member of the family of so-called cytochrome P450 enzymes, which owe their catalytic activity to the same heme group that binds oxygen in hemoglobin in the blood. They were able to expand its substrate scope by using organic acids to simulate substrate binding. The carboxylic acid group activates the H2O2 oxidant, which finally results in oxidation of the heme iron atom and generation of the active species.
This "decoy" approach allows epoxidation of styrene, which cannot normally be achieved with P450 enzymes. When an asymmetric decoy is used, such as the common pain reliever ibuprofen, the epoxidation proceeds stereoselectively: Only the desired molecule is produced, but not its mirror image, which can make the difference between a drug and a poison.
Further optimization of the system both in terms of decoy molecule and P450 mutant should yield higher catalytic activity and better stereoselectivity. This method should prove valuable in expanding the use of enzymes in organic synthesis.
Original publication
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
New approach in the treatment of non-alcoholic fatty liver disease - Resistant starch, such as that found in green bananas, may play an important role in treatment of non-alcoholic fatty liver disease in the future
New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction
Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox - HalcyGen to begin Marketing Authorisation Application for Regulators in Europe
Evotec Receives a Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
UF study strengthens concerns about long-term use of certain painkillers
Scientists at Almac and Queen’s University Belfast discover novel approach to treat cancer patients.
Restoring chemotherapy sensitivity by boosting microRNA levels
Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer
